Last reviewed · How we verify
Bimatoprost .03% sterile ophthalmic solution
At a glance
| Generic name | Bimatoprost .03% sterile ophthalmic solution |
|---|---|
| Also known as | Timolol Maleate 0.5%, Brimonidine Tartarate 0.2%, Bimatoprost 0.03%, Lumigan |
| Sponsor | Federal University of São Paulo |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Triplenex (triple Fixed Combination) Use Evaluation in Patients with Glaucoma (PHASE4)
- Comparison of Latanoprost With Travoprost and Bimatoprost in Patients With Elevated IOP. A 12-weeks, Masked Evaluator, Phase IV Multi-center Study in the US (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: